BR112012000609A2 - piperaziniletil 3-aminopirrolidine derivados como antagonistas ccr2 - Google Patents
piperaziniletil 3-aminopirrolidine derivados como antagonistas ccr2Info
- Publication number
- BR112012000609A2 BR112012000609A2 BR112012000609A BR112012000609A BR112012000609A2 BR 112012000609 A2 BR112012000609 A2 BR 112012000609A2 BR 112012000609 A BR112012000609 A BR 112012000609A BR 112012000609 A BR112012000609 A BR 112012000609A BR 112012000609 A2 BR112012000609 A2 BR 112012000609A2
- Authority
- BR
- Brazil
- Prior art keywords
- piperazinylethyl
- ccr2 antagonists
- aminopyrrolidine derivatives
- aminopyrrolidine
- derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/14—Nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020090063136A KR101151415B1 (ko) | 2009-07-10 | 2009-07-10 | Ccr2 길항제로서의 피페라지닐에틸 3-아미노피롤리딘 유도체 |
| PCT/KR2010/003790 WO2011004972A2 (ko) | 2009-07-10 | 2010-06-11 | Ccr2 길항제로서의 피페라지닐에틸 3-아미노피롤리딘 유도체 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012000609A2 true BR112012000609A2 (pt) | 2015-10-06 |
Family
ID=43429638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012000609A BR112012000609A2 (pt) | 2009-07-10 | 2010-06-11 | piperaziniletil 3-aminopirrolidine derivados como antagonistas ccr2 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US8575173B2 (pt) |
| EP (1) | EP2452939B1 (pt) |
| JP (1) | JP5474189B2 (pt) |
| KR (1) | KR101151415B1 (pt) |
| CN (1) | CN102498109B (pt) |
| BR (1) | BR112012000609A2 (pt) |
| CA (1) | CA2767734A1 (pt) |
| RU (1) | RU2012104633A (pt) |
| WO (1) | WO2011004972A2 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101318656B1 (ko) * | 2010-10-08 | 2013-10-16 | 양지화학 주식회사 | 항천식 활성을 가진 3-아미노피롤리딘 유도체를 포함하는 약학 조성물 |
| KR101437067B1 (ko) * | 2012-09-19 | 2014-09-05 | 이화여자대학교 산학협력단 | 항-cxcl2 또는 항-cxcr2 단일클론 항체를 포함하는 이식편대숙주 질환의 예방 또는 치료용 약학적 조성물 |
| CN105902546B (zh) * | 2014-05-26 | 2019-01-18 | 中国医学科学院医药生物技术研究所 | 取代的哌嗪-1,4-二酰胺类化合物在制备治疗和/或预防炎症反应的药中的应用 |
| MX382659B (es) | 2014-05-28 | 2025-03-11 | Bayer Cropscience Ag | Proceso para la preparación de derivados de tiazol. |
| EP3833762A4 (en) | 2018-08-09 | 2022-09-28 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK285729B6 (sk) | 1997-11-18 | 2007-07-06 | Teijin Pharma Limited | Zlúčenina derivátov cyklických amínov a jej použitie |
| CA2373942A1 (en) * | 1999-05-18 | 2000-11-23 | Teijin Limited | Remedies or prophylactis for diseases in association with chemokines |
| WO2003075853A2 (en) * | 2002-03-08 | 2003-09-18 | Bristol-Myers Squibb Company | Cyclic derivatives as modulators of chemokine receptor activity |
| EP1565436B1 (en) | 2002-11-27 | 2012-04-25 | Incyte Corporation | 3-aminopyrrolidine derivatives as modulators of chemokine receptors |
| US7378409B2 (en) * | 2003-08-21 | 2008-05-27 | Bristol-Myers Squibb Company | Substituted cycloalkylamine derivatives as modulators of chemokine receptor activity |
| KR20080052683A (ko) * | 2003-12-18 | 2008-06-11 | 인사이트 코포레이션 | 케모킨 수용체의 조절제로서의3-사이클로알킬아미노피롤리딘 유도체 |
| CN101065374A (zh) | 2004-09-28 | 2007-10-31 | 詹森药业有限公司 | 取代的二哌啶化学引诱物细胞因子受体2拮抗剂 |
| PA8653301A1 (es) * | 2004-11-22 | 2006-11-09 | Incyte Corp Incyte Corp | Sales de la n-[2-({(3r)-1-[trans-4-hidroxi-4-(6-metoxipiridin-3-il) ciclohexil)pirrolidin |
| WO2007053495A2 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| WO2007053499A2 (en) | 2005-11-01 | 2007-05-10 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of ccr2 |
| US8067457B2 (en) * | 2005-11-01 | 2011-11-29 | Millennium Pharmaceuticals, Inc. | Compounds useful as antagonists of CCR2 |
| WO2007106797A2 (en) | 2006-03-14 | 2007-09-20 | Janssen Pharmaceutica, Nv | A method of use for substituted dipiperidine ccr2 antagonists |
-
2009
- 2009-07-10 KR KR1020090063136A patent/KR101151415B1/ko not_active Expired - Fee Related
-
2010
- 2010-06-11 CN CN201080031168.9A patent/CN102498109B/zh not_active Expired - Fee Related
- 2010-06-11 CA CA2767734A patent/CA2767734A1/en not_active Abandoned
- 2010-06-11 WO PCT/KR2010/003790 patent/WO2011004972A2/ko not_active Ceased
- 2010-06-11 JP JP2012519459A patent/JP5474189B2/ja not_active Expired - Fee Related
- 2010-06-11 EP EP10797246.5A patent/EP2452939B1/en active Active
- 2010-06-11 BR BR112012000609A patent/BR112012000609A2/pt not_active IP Right Cessation
- 2010-06-11 US US13/383,104 patent/US8575173B2/en not_active Expired - Fee Related
- 2010-06-11 RU RU2012104633/04A patent/RU2012104633A/ru unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2011004972A2 (ko) | 2011-01-13 |
| CA2767734A1 (en) | 2011-01-13 |
| KR101151415B1 (ko) | 2012-06-01 |
| WO2011004972A3 (ko) | 2011-05-19 |
| JP5474189B2 (ja) | 2014-04-16 |
| EP2452939B1 (en) | 2014-03-26 |
| US20120190689A1 (en) | 2012-07-26 |
| KR20110005532A (ko) | 2011-01-18 |
| RU2012104633A (ru) | 2013-11-20 |
| US8575173B2 (en) | 2013-11-05 |
| JP2012532865A (ja) | 2012-12-20 |
| EP2452939A4 (en) | 2012-12-26 |
| CN102498109B (zh) | 2014-04-16 |
| CN102498109A (zh) | 2012-06-13 |
| EP2452939A2 (en) | 2012-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1016189A2 (pt) | compostos de 4-azetidinil-1-fenil-ciclohexano antagonistas de ccr2 | |
| BRPI1015038A2 (pt) | derivados espiro azacíclicos como inibidores de hsl | |
| BR112012002662A2 (pt) | derivados de bis-benzimidazol | |
| BR112012004969A2 (pt) | derivados de bis-benzimidazol | |
| BRPI1013821A2 (pt) | piridinas substituídas como antagonistas de ccr3. | |
| BRPI1011694A2 (pt) | similadores de categoria | |
| EP2419608A4 (en) | ROTATING MACHINE WITH AUBES CONTROLLED BY ROLLS | |
| UY3955Q (es) | Carrocería | |
| BRPI1013246A2 (pt) | derivados de benzofuralina | |
| BR112012002828A2 (pt) | derivados de 5-fluorpirimidinona | |
| BRPI0810462A2 (pt) | Derivados de quinolina-carboxamida como antagonistas de p2y12 | |
| ECSP12011999A (es) | Derivados benzamida sustituidos | |
| BR112012005616A2 (pt) | compostos antivirais heterocíclicos | |
| BRPI0817061A2 (pt) | Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3 | |
| BRPI1014077A2 (pt) | Derivados de tiazolilperidina como fungicidas | |
| BRPI1010852A2 (pt) | compostos antivirais heterocíclicos | |
| EP2396152A4 (en) | Router | |
| BRPI1013844A2 (pt) | derivados de piridina-isoxazol | |
| BRPI1016266A2 (pt) | compostos antivirais heterocíclicos | |
| BRPI0925050A2 (pt) | Compostos heterocíclicos como inibidores de mek | |
| BRPI1014454A2 (pt) | derivados de isoxazol-pirazol | |
| DE112010001215A5 (de) | Gurtaufrollersystem mit einsteuerglied | |
| BR112012002810A2 (pt) | derivados de n1-acil-5-fluoropirimidinona | |
| ECSP12011977A (es) | Derivados de etinilo | |
| BRPI1016207A2 (pt) | compostos de 4-azetidinil-1-heteroaril-ciclohexano antagonistas de ccr2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 4A E 5A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2344 DE 08-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |